Drug-Induced Thrombotic Microangiopathy

 

 Buy Article Permissions and Reprints

ABSTRACT

Drug-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome (TTP/HUS) has been recognized for several years. The most commonly implicated drugs are mitomycin-C, cyclosporine, quinine, and ticlopidine. As with idiopathic cases of TTP/HUS, basic science discoveries in the late 1990s now suggest that the likely mechanisms by which these agents lead to a thrombotic microangiopathy (TMA) include either an immune-mediated phenomenon involving the ADAMTS13 metalloprotease or direct endothelial toxicity. This article reviews the current understanding of the pathogenesis, the clinical and laboratory features, and the recommended treatments, prognosis, and outcomes of drug-associated TMA.

REFERENCES

• 1 Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease.  Proc NY Pathol Soc. 1924;  24 21-24
  PubMedGoogle Scholar
• 2 Vesely S K, George J N, Lämmle B et al.. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients.  Blood. 2003;  102 60-68
  CrossrefPubMedGoogle Scholar
• 3 Zheng X L, Kaufman R M, Goodnough L T, Sadler J E. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura.  Blood. 2004;  103 4043-4049
  CrossrefPubMedGoogle Scholar
• 4 Veyradier A, Obert B, Houllier A et al.. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases.  Blood. 2001;  98 1765-1772
  CrossrefPubMedGoogle Scholar
• 5 Miller D P, Kaye J A, Shea K et al.. Incidence of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome.  Epidemiology. 2004;  15 208-215
  CrossrefPubMedGoogle Scholar
• 6 Sadler J E, Moake J L, Miyata T, George J N. Recent advances in thrombotic thrombocytopenic purpura.  Hematology (Am Soc Hematol Educ Program). 2004;  407-423
  CrossrefPubMedGoogle Scholar
• 7 Lian EC-Y. Pathogenesis of thrombotic thrombocytopenic purpura: ADAMTS13 deficiency and beyond.  Semin Thromb Hemost. 2005;  31 625-632
  Article in Thieme ConnectPubMedGoogle Scholar
• 8 Moake J L, Rudy C K, Troll J H et al.. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura.  N Engl J Med. 1982;  307 1432-1435
  CrossrefPubMedGoogle Scholar
• 9 Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis.  Blood. 1996;  87 4223-4234
  CrossrefPubMedGoogle Scholar
• 10 Tsai H M. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion.  Blood. 1996;  87 4235-4244
  CrossrefPubMedGoogle Scholar
• 11 Levy G G, Nichols W C, Lian E C et al.. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.  Nature. 2001;  413 488-494
  CrossrefPubMedGoogle Scholar
• 12 Furlan M, Robles R, Galbusera M et al.. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.  N Engl J Med. 1998;  339 1578-1584
  CrossrefPubMedGoogle Scholar
• 13 Tsai H M, Lian E C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.  N Engl J Med. 1998;  339 1585-1594
  CrossrefPubMedGoogle Scholar
• 14 Medina P J, Sipols J M, George J N. Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.  Curr Opin Hematol. 2001;  8 286-293
  CrossrefPubMedGoogle Scholar
• 15 Gottschall J L, Elliot W, Lianos E et al.. Quinine-induced immune thrombocytopenia associated with hemolytic uremic syndrome: a new clinical entity.  Blood. 1991;  77 306-310
  PubMedGoogle Scholar
• 16 Tsai H M, Rice L, Sarode R et al.. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura.  Ann Intern Med. 2000;  132 794-799
  PubMedGoogle Scholar
• 17 Mauro M, Zlatopolskiy A, Raife T J, Laurence J. Thienopyridine-linked thrombotic microangiopathy: association with endothelial cell apoptosis and activation of MAP kinase signalling cascades.  Br J Haematol. 2004;  124 200-210
  CrossrefPubMedGoogle Scholar
• 18 Valavaara R, Nordman E. Renal complications of mitomycin C therapy with special reference to the total dose.  Cancer. 1985;  55 47-50
  PubMedGoogle Scholar
• 19 Lesesne J B, Rothschild N, Erickson B et al.. Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry.  J Clin Oncol. 1989;  7 781-789
  CrossrefPubMedGoogle Scholar
• 20 Leach J W, Pham T, Diamandidis D, George J N. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) following treatment with deoxycoformycin in a patient with cutaneous T-cell lymphoma (Sezary syndrome): a case report.  Am J Hematol. 1999;  61 268-270
  CrossrefPubMedGoogle Scholar
• 21 Ravandi-Kashani F, Cortes J, Talpaz M, Kantarjian H M. Thrombotic microangiopathy associated with interferon therapy for patients with chronic myelogenous leukemia: coincidence or true side effect?.  Cancer. 1999;  85 2583-2588
  CrossrefPubMedGoogle Scholar
• 22 Al-Zahrani H, Gupta V, Minden M D et al.. Vascular events associated with alpha interferon therapy.  Leuk Lymphoma. 2003;  44 471-475
  CrossrefPubMedGoogle Scholar
• 23 Humphreys B D, Sharman J P, Henderson J M et al.. Gemcitabine-associated thrombotic microangiopathy.  Cancer. 2004;  100 2664-2670
  CrossrefPubMedGoogle Scholar
• 24 Gordon L I, Kwaan H C. Thrombotic microangiopathy manifesting as thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in the cancer patient.  Semin Thromb Hemost. 1999;  25 217-221
  Article in Thieme ConnectPubMedGoogle Scholar
• 25 Cantrell Jr J E, Phillips T M, Schein P S. Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy.  J Clin Oncol. 1985;  3 723-734
  PubMedGoogle Scholar
• 26 Proia A D, Harden E A, Silberman H R. Mitomycin-induced hemolytic-uremic syndrome.  Arch Pathol Lab Med. 1984;  108 959-962
  PubMedGoogle Scholar
• 27 Doll D C, Weiss R B, Issell B F. Mitomycin: ten years after approval for marketing.  J Clin Oncol. 1985;  3 276-286
  PubMedGoogle Scholar
• 28 Nagaya S, Wada H, Oka K et al.. Hemostatic abnormalities and increased vascular endothelial cell markers in patients with red cell fragmentation syndrome induced by mitomycin C.  Am J Hematol. 1995;  50 237-243
  CrossrefPubMedGoogle Scholar
• 29 Fung M C, Storniolo A M, Nguyen B et al.. A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy.  Cancer. 1999;  85 2023-2032
  PubMedGoogle Scholar
• 30 Walter R B, Joerger M, Pestalozzi B C. Gemcitabine-associated hemolytic-uremic syndrome.  Am J Kidney Dis. 2002;  40 E16
  CrossrefPubMedGoogle Scholar
• 31 Al Aly Z, Philoctete Ashley J M, Gellens M E, Gonzalez E A. Thrombotic thrombocytopenic purpura in a patient treated with imatinib mesylate: true association or mere coincidence?.  Am J Kidney Dis. 2005;  45 762-768
  CrossrefPubMedGoogle Scholar
• 32 Helmly R B, Bergin J J, Shulman N R. Quinine-induced purpura. Observation on antibody titers.  Arch Intern Med. 1967;  120 59-62
  CrossrefPubMedGoogle Scholar
• 33 Gottschall J L, Neahring B, McFarland J G et al.. Quinine-induced immune thrombocytopenia with hemolytic uremic syndrome: clinical and serological findings in nine patients and review of literature.  Am J Hematol. 1994;  47 283-289
  CrossrefPubMedGoogle Scholar
• 34 Maguire R B, Stroncek D F, Campbell A C. Recurrent pancytopenia, coagulopathy, and renal failure associated with multiple quinine-dependent antibodies.  Ann Intern Med. 1993;  119 215-217
  PubMedGoogle Scholar
• 35 Kojouri K, Vesely S K, George J N. Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: frequency, clinical features, and long-term outcomes.  Ann Intern Med. 2001;  135 1047-1051
  CrossrefPubMedGoogle Scholar
• 36 Baliga R S, Wingo C S. Quinine induced HUS-TTP: an unusual presentation.  Am J Med Sci. 2003;  326 378-380
  PubMedGoogle Scholar
• 37 PDR for Herbal Medicines .1st ed. Montvale, NJ; Medical Economics Co 1998
  Google Scholar
• 38 Reynolds J C, Agodoa L Y, Yuan C M, Abbott K C. Thrombotic microangiopathy after renal transplantation in the United States.  Am J Kidney Dis. 2003;  42 1058-1068
  CrossrefPubMedGoogle Scholar
• 39 George J N, Li X, McMinn J R et al.. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma.  Transfusion. 2004;  44 294-304
  CrossrefPubMedGoogle Scholar
• 40 Jeejeebhoy F M, Zaltzman J S. Thrombotic microangiopathy in association with cytomegalovirus infection in a renal transplant patient: a new treatment strategy.  Transplantation. 1998;  65 1645-1648
  PubMedGoogle Scholar
• 41 Ramasubbu K, Mullick T, Koo A et al.. Thrombotic microangiopathy and cytomegalovirus in liver transplant recipients: a case-based review.  Transpl Infect Dis. 2003;  5 98-103
  CrossrefPubMedGoogle Scholar
• 42 Schwimmer J, Nadasdy T A, Spitalnik P F et al.. De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy.  Am J Kidney Dis. 2003;  41 471-479
  CrossrefPubMedGoogle Scholar
• 43 Singh N, Gayowski T, Marino I R. Hemolytic uremic syndrome in solid-organ transplant recipients.  Transpl Int. 1996;  9 68-75
  CrossrefPubMedGoogle Scholar
• 44 Zarifian A, Meleg-Smith S, O'Donovan R et al.. Cyclosporine-associated thrombotic microangiopathy in renal allografts.  Kidney Int. 1999;  55 2457-2466
  CrossrefPubMedGoogle Scholar
• 45 Trimarchi H M, Truong L D, Brennan S et al.. FK506-associated thrombotic microangiopathy: report of two cases and review of the literature.  Transplantation. 1999;  67 539-544
  CrossrefPubMedGoogle Scholar
• 46 Wiener Y, Nakhleh R E, Lee M W et al.. Prognostic factors and early resumption of cyclosporin A in renal allograft recipients with thrombotic microangiopathy and hemolytic uremic syndrome.  Clin Transplant. 1997;  11 157-162
  PubMedGoogle Scholar
• 47 Zent R, Katz A, Quaggin S et al.. Thrombotic microangiopathy in renal transplant recipients treated with cyclosporin A.  Clin Nephrol. 1997;  47 181-186
  PubMedGoogle Scholar
• 48 McCauley J, Bronsther O, Fung J et al.. Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506.  Lancet. 1989;  2 1516
  PubMedGoogle Scholar
• 49 Myers J N, Shabshab S F, Burton N A, Nathan S D. Successful use of cyclosporine in a lung transplant recipient with tacrolimus-associated hemolytic uremic syndrome.  J Heart Lung Transplant. 1999;  18 1024-1026
  CrossrefPubMedGoogle Scholar
• 50 Pham P T, Peng A, Wilkinson A H et al.. Cyclosporine and tacrolimus-associated thrombotic microangiopathy.  Am J Kidney Dis. 2000;  36 844-850
  PubMedGoogle Scholar
• 51 Abraham K A, Little M A, Dorman A M, Walshe J J. Hemolytic-uremic syndrome in association with both cyclosporine and tacrolimus.  Transpl Int. 2000;  13 443-447
  CrossrefPubMedGoogle Scholar
• 52 Hochstetler L A, Flanigan M J, Lager D J. Transplant-associated thrombotic microangiopathy: the role of IgG administration as initial therapy.  Am J Kidney Dis. 1994;  23 444-450
  PubMedGoogle Scholar
• 53 Iacopino P, Pucci G, Arcese W et al.. Severe thrombotic microangiopathy: an infrequent complication of bone marrow transplantation. Gruppo Italiano Trapianto Midollo Osseo (GITMO).  Bone Marrow Transplant. 1999;  24 47-51
  CrossrefPubMedGoogle Scholar
• 54 Elliott M A, Nichols Jr W L, Plumhoff E A et al.. Posttransplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary review.  Mayo Clin Proc. 2003;  78 421-430
  CrossrefPubMedGoogle Scholar
• 55 Arai S, Allan C, Streiff M et al.. Von Willebrand factor-cleaving protease activity and proteolysis of von Willebrand factor in bone marrow transplant-associated thrombotic microangiopathy.  Hematol J. 2001;  2 292-299
  CrossrefPubMedGoogle Scholar
• 56 Palestine A G, Austin III H A, Balow J E et al.. Renal histopathologic alterations in patients treated with cyclosporine for uveitis.  N Engl J Med. 1986;  314 1293-1298
  PubMedGoogle Scholar
• 57 Rodriguez F, Krayenbuhl J C, Harrison W B et al.. Renal biopsy findings and followup of renal function in rheumatoid arthritis patients treated with cyclosporin A. An update from the International Kidney Biopsy Registry.  Arthritis Rheum. 1996;  39 1491-1498
  PubMedGoogle Scholar
• 58 Holler E, Kolb H J, Hiller E et al.. Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation.  Blood. 1989;  73 2018-2024
  PubMedGoogle Scholar
• 59 Zoja C, Furci L, Ghilardi F et al.. Cyclosporin-induced endothelial cell injury.  Lab Invest. 1986;  55 455-462
  PubMedGoogle Scholar
• 60 Brown Z, Neild G H. Cyclosporine inhibits prostacyclin production by cultured human endothelial cells.  Transplant Proc. 1987;  19(1 pt 2) 1178-1180
  PubMedGoogle Scholar
• 61 Garcia-Maldonado M, Kaufman C E, Comp P C. Decrease in endothelial cell-dependent protein C activation induced by thrombomodulin by treatment with cyclosporine.  Transplantation. 1991;  51 701-705
  PubMedGoogle Scholar
• 62 Pham P T, Danovitch G M, Wilkinson A H et al.. Inhibitors of ADAMTS13: a potential factor in the cause of thrombotic microangiopathy in a renal allograft recipient.  Transplantation. 2002;  74 1077-1080
  PubMedGoogle Scholar
• 63 Roberts P, Follette D, Allen R et al.. Cyclosporine A-associated thrombotic thrombocytopenic purpura following lung transplantation.  Transplant Proc. 1998;  30 1512-1513
  CrossrefPubMedGoogle Scholar
• 64 Schmidt R J, Venkat K K, Dumler F. Hemolytic-uremic syndrome in a renal transplant recipient on FK 506 immunosuppression.  Transplant Proc. 1991;  23 3156-3157
  PubMedGoogle Scholar
• 65 Burke G W, Ciancio G, Cirocco R et al.. Microangiopathy in kidney and simultaneous pancreas/kidney recipients treated with tacrolimus: evidence of endothelin and cytokine involvement.  Transplantation. 1999;  68 1336-1342
  PubMedGoogle Scholar
• 66 Randhawa P S, Tsamandas A C, Magnone M et al.. Microvascular changes in renal allografts associated with FK506 (Tacrolimus) therapy.  Am J Surg Pathol. 1996;  20 306-312
  CrossrefPubMedGoogle Scholar
• 67 Moutabarrik A, Ishibashi M, Fukunaga M et al.. FK 506 mechanism of nephrotoxicity: stimulatory effect on endothelin secretion by cultured kidney cells and tubular cell toxicity in vitro.  Transplant Proc. 1991;  23 3133-3136
  PubMedGoogle Scholar
• 68 Nakazawa Y, Hashikura Y, Urata K et al.. Von Willebrand factor-cleaving protease activity in thrombotic microangiopathy after living donor liver transplantation: a case report.  Liver Transpl. 2003;  9 1328-1333
  CrossrefPubMedGoogle Scholar
• 69 Tripodi A, Chantarangkul V, Bohm M et al.. Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas.  J Thromb Haemost. 2004;  2 1601-1609
  CrossrefPubMedGoogle Scholar
• 70 Gharpure V S, Devine S M, Holland H K et al.. Thrombotic thrombocytopenic purpura associated with FK506 following bone marrow transplantation.  Bone Marrow Transplant. 1995;  16 715-716
  PubMedGoogle Scholar
• 71 Lin C C, King K L, Chao Y W et al.. Tacrolimus-associated hemolytic uremic syndrome: a case analysis.  J Nephrol. 2003;  16 580-585
  PubMedGoogle Scholar
• 72 Savi P, Herbert J M. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis.  Semin Thromb Hemost. 2005;  31 174-183
  Article in Thieme ConnectPubMedGoogle Scholar
• 73 Evens A M, Kwaan H C, Kaufman D B, Bennett C L. TTP/HUS occurring in a simultaneous pancreas/kidney transplant recipient after clopidogrel treatment: evidence of a nonimmunological etiology.  Transplantation. 2002;  74 885-887
  CrossrefPubMedGoogle Scholar
• 74 Page Y, Tardy B, Zeni F et al.. Thrombotic thrombocytopenic purpura related to ticlopidine.  Lancet. 1991;  337 774-776
  CrossrefPubMedGoogle Scholar
• 75 Bennett C L, Weinberg P D, Rozenberg-Ben-Dror K et al.. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases.  Ann Intern Med. 1998;  128 541-544
  CrossrefPubMedGoogle Scholar
• 76 Steinhubl S R, Tan W A, Foody J M, Topol E J. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of platelet IIb/IIIa inhibitor for stenting.  JAMA. 1999;  281 806-810
  CrossrefPubMedGoogle Scholar
• 77 Bennett C L, Davidson C J, Raisch D W et al.. Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention.  Arch Intern Med. 1999;  159 2524-2528
  CrossrefPubMedGoogle Scholar
• 78 [No authors listed] . A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.  Lancet. 1996;  348 1329-1339
  CrossrefPubMedGoogle Scholar
• 79 Yusuf S, Zhao F, Mehta S R et al.. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.  N Engl J Med. 2001;  345 494-502
  CrossrefPubMedGoogle Scholar
• 80 Bennett C L, Connors J M, Carwile J M et al.. Thrombotic thrombocytopenic purpura associated with clopidogrel.  N Engl J Med. 2000;  342 1773-1777
  CrossrefPubMedGoogle Scholar
• 81 Chinnakotla S, Leone J P, Fidler M E et al.. Clopidogrel-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in a kidney/pancreas transplant recipient.  Transplantation. 2000;  70 550-552
  PubMedGoogle Scholar
• 82 Nara W, Ashley I, Rosner F. Thrombotic thrombocytopenic purpura associated with clopidogrel administration: case report and brief review.  Am J Med Sci. 2001;  322 170-172
  PubMedGoogle Scholar
• 83 Zakarija A, Bandarenko N, Pandey D K et al.. Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration.  Stroke. 2004;  35 533-537
  CrossrefPubMedGoogle Scholar
• 84 Manor S M, Guillory G S, Jain S P. Clopidogrel-induced thrombotic thrombocytopenic purpura-hemolytic uremic syndrome after coronary artery stenting.  Pharmacotherapy. 2004;  24 664-666
  PubMedGoogle Scholar
• 85 Andersohn F, Hagmann G, Garbe E. Thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome associated with clopidogrel: report of two new cases.  Heart. 2004;  90 e57
  CrossrefPubMedGoogle Scholar
• 86 von Mach M A, Eich A, Weilemann L S, Munzel T. Subacute coronary stent thrombosis in a patient developing clopidogrel associated thrombotic thrombocytopenic purpura.  Heart. 2005;  91 e14
  CrossrefPubMedGoogle Scholar
• 87 Orimo S, Ozawa E, Yagi H et al.. Simple plasma exchange reduced autoantibody to von Willebrand factor-cleaving protease in a Japanese man with ticlopidine-associated thrombotic thrombocytopenic purpura.  J Intern Med. 2002;  251 280-281
  CrossrefPubMedGoogle Scholar
• 88 Sugio Y, Okamura T, Shimoda K et al.. Ticlopidine-Associated thrombotic thrombocytopenic purpura with an IgG-type inhibitor to von Willebrand factor-cleaving protease activity.  Int J Hematol. 2001;  74 347-351
  PubMedGoogle Scholar
• 89 Chen D K, Kim J S, Sutton D M. Thrombotic thrombocytopenic purpura associated with ticlopidine use: a report of 3 cases and review of the literature.  Arch Intern Med. 1999;  159 311-314
  CrossrefPubMedGoogle Scholar

Charles BennettM.D. 

Professor, Jesse Brown VAMC, 333 East Huron, Suite 277, Chicago, IL 60611

Email: cbenne@northwestern.edu